Katsuaki Maehara: Genome doubling identified as a key factor in resistance for EGFRm lung cancer
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X about a paper by Maise Al Bakir et al. published in Nature:
“EGFRm Lung cancer.
A study of recurrent cases treated with osimertinib plus tumor-specific neoantigen. Most of them transformed to small cell lineages, and neoantigen expression was decreased in liver metastasis cases.
The paper found that genome doubling was behind this acquisition of resistance and that phylogenetic analysis would be useful.”
“Clonal driver neoantigen loss under EGFR TKI and immune selection pressures”
Authors: Maise Al Bakir, James Reading, Samuel Gamble, Rachel Rosenthal, Imran Uddin, Sine Reker Hadrup, Benny Chain, Sergio Quezada, Nicholas McGranahan, Charles Swanton et al.
More posts featuring Katsuaki Maehara.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023